Skip to main content
Fig. 1 | Health and Quality of Life Outcomes

Fig. 1

From: Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

Fig. 1

Mixed-effects model analysis of FACT-Leu. a, FWB; b, EWB; c, PWB; d, S/FWB; e, LeuS; f, TOI score; g, FACT-Leu total score. Curves above the x-axis indicate positive effects, and curves below the axis show negative effects. Gray area denotes MID range. aP = 0.0525 for treatment difference. bP = 0.0192 for treatment difference. cP = 0.0343 for treatment difference. CI confidence interval, EWB emotional well-being, FACT-Leu Functional Assessment of Cancer Therapy–Leukemia, FWB functional well-being, LeuS leukemia-specific symptoms, MID minimally important difference, PWB physical well-being, S/FWB social/family well-being, TOI trial outcome index

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us